{
  "query": "KLRA",
  "resolved": {
    "ticker": "KLRA",
    "cik": "0002096997",
    "title": "Kailera Therapeutics, Inc."
  },
  "signals": [
    {
      "type": "trial_to_filing",
      "headline": "Kailera Therapeutics, Inc. (KLRA) — PHASE3 protocol updated 3 days ago",
      "entity": "Kailera",
      "ticker": "KLRA",
      "cik": "0002096997",
      "tickerConfidence": 0.95,
      "upstream": {
        "event": "Clinical trial status (PHASE3)",
        "detail": "Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes",
        "nctId": "NCT07284901",
        "date": "2028-03-27"
      },
      "observed": {
        "event": "protocol updated 3 days ago",
        "nctId": "NCT07284901"
      },
      "predicted": {
        "event": "SEC 8-K / press release on NDA/BLA filing (FDA submission)",
        "leadTime": "12-24 mo",
        "baseRate": 0.58,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "Phase-transition base rate 57% (Wong/Siah/Lo 2019)",
      "confidence": 0.35,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT07284901",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0002096997&type=8-K"
      }
    },
    {
      "type": "trial_to_filing",
      "headline": "Kailera Therapeutics, Inc. (KLRA) — PHASE3 protocol updated 3 days ago",
      "entity": "Kailera",
      "ticker": "KLRA",
      "cik": "0002096997",
      "tickerConfidence": 0.95,
      "upstream": {
        "event": "Clinical trial status (PHASE3)",
        "detail": "Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes",
        "nctId": "NCT07284979",
        "date": "2028-03-20"
      },
      "observed": {
        "event": "protocol updated 3 days ago",
        "nctId": "NCT07284979"
      },
      "predicted": {
        "event": "SEC 8-K / press release on NDA/BLA filing (FDA submission)",
        "leadTime": "12-24 mo",
        "baseRate": 0.58,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "Phase-transition base rate 57% (Wong/Siah/Lo 2019)",
      "confidence": 0.35,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT07284979",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0002096997&type=8-K"
      }
    },
    {
      "type": "trial_to_filing",
      "headline": "Kailera Therapeutics, Inc. (KLRA) — PHASE3 protocol updated 3 days ago",
      "entity": "Kailera",
      "ticker": "KLRA",
      "cik": "0002096997",
      "tickerConfidence": 0.95,
      "upstream": {
        "event": "Clinical trial status (PHASE3)",
        "detail": "Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes",
        "nctId": "NCT07284875",
        "date": "2028-02-28"
      },
      "observed": {
        "event": "protocol updated 3 days ago",
        "nctId": "NCT07284875"
      },
      "predicted": {
        "event": "SEC 8-K / press release on NDA/BLA filing (FDA submission)",
        "leadTime": "12-24 mo",
        "baseRate": 0.58,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "Phase-transition base rate 57% (Wong/Siah/Lo 2019)",
      "confidence": 0.35,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT07284875",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0002096997&type=8-K"
      }
    },
    {
      "type": "trial_to_filing",
      "headline": "Kailera Therapeutics, Inc. (KLRA) — PHASE2 protocol updated 5 days ago",
      "entity": "Kailera",
      "ticker": "KLRA",
      "cik": "0002096997",
      "tickerConfidence": 0.95,
      "upstream": {
        "event": "Clinical trial status (PHASE2)",
        "detail": "Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity",
        "nctId": "NCT07497880",
        "date": "2027-07-07"
      },
      "observed": {
        "event": "protocol updated 5 days ago",
        "nctId": "NCT07497880"
      },
      "predicted": {
        "event": "SEC 8-K / press release on Phase 3 initiation",
        "leadTime": "18-36 mo",
        "baseRate": 0.29,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "Phase-transition base rate 28% (Wong/Siah/Lo 2019)",
      "confidence": 0.35,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT07497880",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0002096997&type=8-K"
      }
    }
  ],
  "recentFilings": {
    "name": "Kailera Therapeutics, Inc.",
    "sicDescription": "Pharmaceutical Preparations",
    "filings": [
      {
        "form": "8-K",
        "date": "2026-05-26",
        "accession": "0001193125-26-239362",
        "items": "2.02,9.01"
      },
      {
        "form": "8-K",
        "date": "2026-04-20",
        "accession": "0001193125-26-164040",
        "items": "5.03,8.01,9.01"
      }
    ]
  },
  "disclaimer": "Research/informational. NOT investment advice.",
  "generatedAt": "2026-06-21T09:50:25.029Z"
}